The FDA has approved the triple inhaler developed by GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) to treat chronic obstructive pulmonary disease, the companies reported today.
The Trelega Ellipta dry powder inhaler uses fluticasone furoate, umeclidinium and vilanterol to help adults with COPD manage the condition. It is the first once-daily product approved in the U.S. that combines three active molecules in a single inhaler for COPD patients.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA approves GSK’s 3-in-1 Trelega Ellipta inhaler appeared first on MassDevice.
from MassDevice http://ift.tt/2hfm6NE
Cap comentari:
Publica un comentari a l'entrada